RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Conditions: Melanoma Interventions: Biological: Vusolimogene oderparepvec (RP1) Sponsors: Yana Najjar; Replimune Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials